Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Genitourinary Cancers
Are there studies looking at Ra-223 and SBRT for oligometastatic disease in the setting of mCRPC?
Answer from: Radiation Oncologist at Community Practice
Yes, quite a few including one from UCLA- NCT05496959
Sign in or Register to read more
18046
Related Questions
Would you offer salvage radiation for a local recurrence of prostate cancer that was initially treated with SBRT?
Would you offer prostate SBRT to a patient on a TKI?
How do you interpret PSMA/PET with focal prostate activity after XRT currently on ADT with stable PSA?
How aggressive would you be in irradiating asymptomatic bone metastases in a patient with metastatic prostate cancer?
In a patient with very high risk prostate cancer opting for prostatectomy, when, if ever, do you recommend neoadjuvant ADT?
Given results of BCON trial, do you add carbogen and nicotinamide for patients receiving definitive radiotherapy for bladder cancer, particularly for non-cisplatin eligible candidates?
When is it safe for a rectal biopsy in a patient with prior prostate radiation?
Would you consider adding abiraterone to ADT and salvage RT in a prostate cancer patient with pN1 disease at radical prostatectomy?
Does the presence of Atypical Intraductal Proliferation (AIP) on prostate needle biopsy influence your risk stratification?
How would you treat a non-surgical T1 high grade urothelial carcinoma of the bladder with a remote history of prostate cancer?